<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052455</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258428</org_study_id>
    <secondary_id>MRC-BR12</secondary_id>
    <secondary_id>EU-20114</secondary_id>
    <secondary_id>ISRCTN83176944</secondary_id>
    <nct_id>NCT00052455</nct_id>
  </id_info>
  <brief_title>Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma</brief_title>
  <official_title>A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which regimen of chemotherapy is more effective in treating recurrent malignant&#xD;
      glioma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of temozolomide alone to&#xD;
      that of procarbazine, lomustine, and vincristine in treating patients who have recurrent&#xD;
      malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of temozolomide vs procarbazine, lomustine, and vincristine, in&#xD;
           terms of overall survival, in patients with recurrent malignant glioma.&#xD;
&#xD;
        -  Compare progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare progression-free survival at 12 weeks in patients treated with two different&#xD;
           schedules of temozolomide.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with two different schedules of&#xD;
           temozolomide.&#xD;
&#xD;
        -  Compare toxic effects of two different schedules of temozolomide in these patients.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I:Patients are randomized to 1 of 2 treatment schedules:&#xD;
&#xD;
             -  Schedule 1: Patients receive oral temozolomide once daily on days 1-5.&#xD;
&#xD;
             -  Schedule 2:Patients receive oral temozolomide once daily on days 1-21. Treatment on&#xD;
                both schedules repeats every 4 weeks for a maximum of 9 courses in the absence of&#xD;
                disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II:Patients receive oral lomustine and vincristine IV on day 1 and oral procarbazine&#xD;
           on days 1-21. Treatment repeats every 6 weeks for a maximum of 6 courses in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and at 12 and 24 weeks.&#xD;
&#xD;
      Patients are followed every 12 weeks.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 500 patients (250 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 12 weeks (Arm II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by EORTC QLQ-C30 and BTM</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed anaplastic astrocytoma, glioblastoma multiforme, or&#xD;
             gliosarcoma&#xD;
&#xD;
               -  WHO grade III or IV at diagnosis or relapse&#xD;
&#xD;
          -  Must have undergone primary therapy including radiotherapy&#xD;
&#xD;
          -  Must be in first recurrence confirmed by CT scan or MRI&#xD;
&#xD;
          -  Evaluable disease by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 1 month&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Total and direct bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT less than 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  BUN less than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent serious illness&#xD;
&#xD;
          -  Considered fit to receive chemotherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for glioma&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 months since prior radiotherapy&#xD;
&#xD;
          -  No prior radiosurgery, interstitial radiotherapy, or brachytherapy for glioma&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior debulking surgery for recurrent disease allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Clawson</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Research Council</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Council Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins VP, Lee SM. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010 Oct 20;28(30):4601-8. doi: 10.1200/JCO.2009.27.1932. Epub 2010 Sep 20.</citation>
    <PMID>20855843</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

